Significant Ownership of Hanmi Pharmaceutical Co., Ltd.

Signature - Title
/s/ Haegon Shin - Haegon Shin, Managing Director, Global Business Division
Location
Seoul, Korea, Republic of
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Hanmi Pharmaceutical Co., Ltd..

Notify me when Hanmi Pharmaceutical Co., Ltd. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Hanmi Pharmaceutical Co., Ltd.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
APTOF Aptose Biosciences Inc. Common Shares 20% $115,375 508,710 Hanmi Pharmaceutical Co., Ltd. 18 Mar 2025

Schedules 13D/G Reported by Hanmi Pharmaceutical Co., Ltd.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.